Comparative Pharmacology
Head-to-head clinical analysis: BLOXIVERZ versus MESTINON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLOXIVERZ versus MESTINON.
BLOXIVERZ vs MESTINON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BLOXIVERZ is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the serotonin transporter (SERT), leading to increased extracellular serotonin levels.
Inhibits acetylcholinesterase, preventing breakdown of acetylcholine and increasing its concentration at cholinergic synapses, thereby enhancing neuromuscular transmission.
10 mg intravenously every 12 hours; may increase to 15 mg every 12 hours based on clinical response.
Myasthenia gravis: 60-150 mg orally every 3-4 hours, up to 1.2 g/day. Extended-release: 180-540 mg orally once or twice daily.
None Documented
None Documented
Terminal half-life 18 hours (range 14-22 h); clinical: steady state in ~3.5 days, dosing adjustments needed in renal impairment.
The terminal elimination half-life is approximately 1.5 to 2 hours in adults. In patients with renal impairment, half-life may be prolonged (up to 6-10 hours in severe impairment), necessitating dose adjustment.
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other routes.
Renal excretion of unchanged drug and metabolites accounts for approximately 80-90% of elimination, with a small fraction (10-20%) eliminated in feces via biliary secretion.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor